Are GLP-1 Weight Loss Drugs Worth the Cost? What the Evidence Shows

The question we hear most in a first weight loss visit is not "which drug works best." It is "can I actually afford this, and is it worth it?" That is the right question to ask. These medications work, but they are expensive, and the honest answer has a few moving parts. Here is what the evidence shows about GLP-1 drugs like semaglutide (Wegovy) and tirzepatide (Zepbound), what they really cost, and how to think about value for your own situation.

Start with the real monthly price

Sticker shock is real. Without insurance, Wegovy carries a list price just under $1,350 per month, and Zepbound sits just above $1,000 (https://www.goodrx.com/classes/glp-1-agonists/glp-1-drugs-cost-and-savings). That is the number most people see first, and it is a fair reason to pause.

The picture is a little softer than that headline, though. Both manufacturers now sell direct cash-pay versions for people paying out of pocket, often in the $300 to $500 range depending on the dose, and some starter doses run lower. Whether you pay the full list price, a cash-pay price, or an insurance copay changes the value math completely. So the first thing we do is figure out what you would actually pay, not what the internet says the drug costs.

What the efficacy data actually shows

The reason these drugs get so much attention is that they work better than anything we have had before. In the STEP 1 trial, adults on semaglutide 2.4 mg lost about 15% of their body weight over 68 weeks alongside lifestyle changes (https://www.nejm.org/doi/full/10.1056/NEJMoa2032183). In SURMOUNT-1, tirzepatide at the 15 mg dose produced 20.9% weight loss at 72 weeks (https://www.nejm.org/doi/full/10.1056/NEJMoa2206038). For context, older weight loss medications typically deliver in the range of 5 to 10%.

Weight is not the whole story, and this is where value starts to shift. In the SELECT trial, semaglutide reduced major cardiovascular events, meaning heart attacks, strokes, and cardiovascular deaths, by about 20% in people with obesity and existing heart disease, even without diabetes (https://www.nejm.org/doi/full/10.1056/NEJMoa2307563). That is a hard outcome, not just a number on a scale. When a medication prevents heart attacks, its value looks different than it does on a pharmacy receipt.

Why "expensive" and "not worth it" are not the same thing

In 2025, the American College of Physicians published a systematic review that looked specifically at the cost-effectiveness of weight loss medications, alongside a companion analysis of their benefits and harms (https://www.acpjournals.org/doi/10.7326/ANNALS-24-03766). We have read both carefully, and the honest summary is this: the answer depends heavily on the price paid and the assumptions used.

Some models find that semaglutide and tirzepatide deliver high clinical value once you credit their downstream benefits, such as fewer heart attacks, delayed diabetes, and less weight-related joint and sleep disease. Other models find the same drugs hard to justify because of their high upfront wholesale price (https://www.acpjournals.org/doi/10.7326/ANNALS-24-03764). Both can be true. A drug that costs over $1,000 a month but prevents a hospitalization, a surgery, or years of diabetes management looks very different across ten years than it does across one.

The practical takeaway is that cheapest and most cost-effective are not the same thing. The right answer depends on your health, your risk, and the price you can actually get.

Where the cheaper medications still make sense

We want to be balanced here, because the GLP-1 conversation can crowd out reasonable options. Older agents like phentermine-topiramate cost a fraction of what the newer drugs cost and still produce meaningful weight loss, often in the 8 to 10% range, per the ACP benefits and harms review (https://www.acpjournals.org/doi/10.7326/ANNALS-24-03764). For some patients, particularly those without heart disease or diabetes who tolerate the medication well, a lower-cost option is a legitimate first choice.

Each medication has its own tradeoffs. Phentermine-topiramate carries specific side effects and cannot be used in pregnancy. Naltrexone-bupropion tends to produce more modest results. Orlistat has the longest safety track record but the smallest effect. None of this is one-size-fits-all, which is exactly why it should be a conversation, not a default. The right medication is the one that fits your biology, your risk profile, and your budget, not simply the newest one.

The catch nobody likes to hear: weight often comes back

Here is the part that matters most for value, and it does not make the ads. These medications treat obesity while you take them; they do not cure it. In the STEP 1 trial extension, people who stopped semaglutide regained about two-thirds of their lost weight within a year (https://pubmed.ncbi.nlm.nih.gov/35441470/).

That is not a willpower failure. Obesity involves lasting changes in appetite and metabolism hormones that do not simply reset after weight loss. GLP-1 medications work in part by correcting those signals, so when the medication stops, the signals drift back. For your budget, this means one thing: think of these drugs the way we think about blood pressure medication, as a long-term plan rather than a short course. A three-month trial that you then stop tends to give you the cost without the lasting benefit. A sustained plan with regular monitoring is where the value lives.

How we think about value with you

The ACP review does not tell us which drug to prescribe for any one person. What it confirms is that evidence-based treatment of obesity can be genuinely worth it, especially for medications with proven benefits beyond weight alone, and especially at a reasonable price. It also gives us permission to say plainly when a cheaper option is the smarter call.

When you come in for a weight evaluation, we look at several things together: your weight and BMI, your labs and blood sugar, your heart risk, your other medications and how you tolerate them, your insurance and pricing situation, and your goals. We are not a GLP-1 clinic. We use these medications when they are the right tool, explain clearly when they are not, and we will never steer you toward something you cannot sustain. We also decline to prescribe compounded semaglutide or tirzepatide, because the FDA has flagged real safety problems with those products (https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss).

The bottom line

GLP-1 drugs are expensive upfront and can be very much worth it over time, particularly when their heart and metabolic benefits are counted and when you stay on a plan. Older medications are cheaper and may be exactly right depending on your situation. Compounded versions are not regulated and not recommended. And stopping any of these early tends to undo both the weight loss and the reason you paid for it.

If you want a straight answer built around your actual numbers rather than a population average, our endocrinology and weight loss program is the place to start. We will review your labs, walk through your options with full transparency on cost, and build a plan you can keep. Book a new-patient visit at nomibeach.health or call us at (786) 744-5152, and see more on our blog for related guidance.